2,695 results on '"Watts, Gerald F."'
Search Results
2. Unexpected gaps in knowledge of familial hypercholesterolaemia among Dutch general practitioners
3. Tissue-specific enhancer–gene maps from multimodal single-cell data identify causal disease alleles
4. Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review
5. Sex-dependent associations of plasma high-density lipoprotein cholesterol and mortality risk in healthy older men and women: two prospective cohort studies
6. Implementation Science: Strategies to Improve Adoption and Adherence to Clinical Practice Guidelines
7. Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis
8. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia
9. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes
10. Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias
11. Contributors
12. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
13. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
14. Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes
15. Induced alternative splicing an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations
16. Metabolic phenotyping of BMI to characterize cardiometabolic risk: evidence from large population-based cohorts
17. A lipidomic based metabolic age score captures cardiometabolic risk independent of chronological age
18. Development and validation of a plasmalogen score as an independent modifiable marker of metabolic health: population based observational studies and a placebo-controlled cross-over study
19. Social cognition correlates of self-management behaviors in patients with familial hypercholesterolemia (FH): A meta-analytic review
20. Addressing genetic and environmental sources of cardiometabolic disease
21. Editorial: Quantitative and qualitative aspects of lipids and lipoproteins in health and disease: nutrition, physiology and genetics
22. Adherence to pharmacotherapy: sine qua non for reducing cumulative risk of premature coronary disease in familial hypercholesterolemia
23. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study
24. Association of plasma high-density lipoprotein cholesterol level with risk of incident dementia: a cohort study of healthy older adults
25. Endothelial Dysfunction in Type 2 Diabetes with an Update on New Interventions
26. Contemporary Aspects of Lp(a) Metabolism and Therapies Based on Tracer Kinetic Studies in Humans
27. How Can Implementation Science Improve the Care of Familial Hypercholesterolaemia?
28. The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder
29. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study
30. Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and not treating with lipoprotein apheresis
31. Application of implementation science for improving the utilization of an international clinical practice guidance on familial hypercholesterolemia
32. Lipoprotein(a) and calcific aortic valve disease: current evidence and future directions
33. Abstract 17120: ARO-ANG3, an Investigational RNAi Therapeutic, Silences the Expression of ANGPTL3 and Decreases Atherogenic Lipoproteins in Patients With Mixed Dyslipidemia: ARCHES-2 Study Results
34. Abstract 12103: Intraindividual Variability in Serial Lipoprotein(a) Concentration Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial
35. Combined population genomic screening for three high-risk conditions in Australia: a modelling study
36. Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand
37. Barriers to and Facilitators of Implementing Guidelines for Detecting Familial Hypercholesterolaemia in Australia
38. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
39. The chromatin landscape of pathogenic transcriptional cell states in rheumatoid arthritis
40. The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases
41. Recent advances in the management and implementation of care for familial hypercholesterolaemia
42. ANGPTL3 as a therapeutic target for treating homozygous familial hypercholesterolaemia: a shot in the arm for evinacumab
43. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
44. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
45. The effect of Vitamin-K1 and Colchicine on Vascular Calcification Activity in subjects with Diabetes Mellitus (ViKCoVaC): A double-blind 2x2 factorial randomized controlled trial
46. Participant experiences of intervention to detect and manage familial hypercholesterolaemia in Australian general practice: A qualitative descriptive study
47. Cost impact of undertaking detection and management of familial hypercholesterolaemia in Australian general practice
48. Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations
49. Hepatic fat as a novel marker for high-risk coronary atherosclerotic plaque features in familial hypercholesterolaemia
50. Predicting intention to participate in self-management behaviors in patients with Familial Hypercholesterolemia: A cross-national study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.